The approval of Syfovre, the first and so far only treatment for geographic atrophy, is a landmark transition in the retina space, comparable to the introduction of anti-VEGF therapies for wet age-related macular degeneration.
“It is a landmark for patients, who historically had nothing, and it is also very meaningful for the field broadly because of all of the failed trials over the last decade. With the approval of a medication that slows the progression of GA with increasing efficacy over time, this has the potential to galvanize the field, (Read more...)